Game-Changing Developments in Alzheimer’s Detection

In a groundbreaking revelation at the Alzheimer's Association International Conference 2025 (AAIC), Neurogen Biomarking unveiled an innovative approach to combating Alzheimer’s Disease (AD) that could slash the time from symptom onset to diagnosis by a staggering 4.5 years. This transformation in care is the result of marrying advanced in-home biomarker testing with cognitive assessments and specialized virtual care, overcoming traditional barriers to early detection.

Bridging Gaps in Early Intervention

The research highlighted during the presentation emphasized a compelling correlation between Neurogen’s TASSO blood collection method and conventional blood draws. This new system not only showcased its efficacy but also pointed towards its ability to triage patients effectively. Designed for individuals worried about memory issues, Neurogen's platform prepares for a national rollout, promising quicker and more equitable access to AD testing technologies.

Insights from Community Pilot Programs

Conducted across three free community events in Chicago and Michigan, the findings of the study represented diverse populations aged 50 and above. Participants engaged in digital cognitive assessments and were assessed through both traditional and innovative blood collection methods. Remarkably, 80% exhibited some level of cognitive impairment, underscoring the significance of timely screening.

Impressive Statistical Outcomes

Among the 455 participants involved in the study, a staggering 26% presented elevated P-tau217 levels, a key biomarker linked to Alzheimer’s pathology. TASSO displayed an impressive 88% accuracy in identifying these elevated levels, streamlining the process from cognitive concerns to intervention down to mere months instead of years.

A New Era in Alzheimer’s Care

Elisabeth Thijssen, PhD and Neurogen’s Chief Scientific Officer, articulated the mission behind this initiative, aiming for widespread rapid adoption of breakthrough technologies in Alzheimer’s diagnostics, thus improving patient outcomes. As traditional waiting periods for specialist consultations can often extend significantly, this virtual care model offers immediate follow-ups with neurologists, allowing for faster action and a personalized healthcare approach.

The Urgent Need for Change

With around 40% of Americans aged 65 and older facing memory challenges — yet fewer than 8% receiving formal diagnoses — there is a critical need for improved access to early detection methodologies. The transition from symptom onset to diagnosis can often take 6 to 8 years, while today's treatments yield the best results when administered early. Neurogen’s innovative solutions could significantly reduce this gap, providing timely interventions when they are most effective.

Join the Movement

Neurogen Biomarking stands at the forefront of a historic shift in Alzheimer’s care, utilizing cutting-edge technology to ensure equitable access to vital screenings and early interventions. As we advance into this new frontier of brain health, the opportunities for improved patient outcomes are limitless. For those concerned about cognitive decline, embracing this revolutionary system may soon be a critical step towards safeguarding their future.